Advertisement
Singapore markets close in 2 hours 49 minutes
  • Straits Times Index

    3,277.20
    -15.93 (-0.48%)
     
  • Nikkei

    37,647.22
    -812.86 (-2.11%)
     
  • Hang Seng

    17,213.22
    +11.95 (+0.07%)
     
  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     
  • Bitcoin USD

    64,239.10
    -2,401.21 (-3.60%)
     
  • CMC Crypto 200

    1,390.15
    +7.57 (+0.55%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • Dow

    38,460.92
    -42.77 (-0.11%)
     
  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     
  • Gold

    2,330.80
    -7.60 (-0.33%)
     
  • Crude Oil

    82.91
    +0.10 (+0.12%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • FTSE Bursa Malaysia

    1,570.29
    -1.19 (-0.08%)
     
  • Jakarta Composite Index

    7,157.23
    -17.30 (-0.24%)
     
  • PSE Index

    6,578.37
    +5.62 (+0.09%)
     

Here's a New Million-Dollar Reason to Buy CRISPR Therapeutics

Here's a New Million-Dollar Reason to Buy CRISPR Therapeutics

CRISPR Therapeutics (NASDAQ: CRSP) is heading for an important moment: the potential approval of its first product, exa-cel to treat blood disorders. First, let's talk a little bit about CRISPR's technology. In T1D, the body destroys islet cells that normally would control blood sugar levels.